Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25555025 | 1.00 | KDM4E (0.68) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| SCHEMBL9677979 | 0.83 | KDM4E (0.70) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| SCHEMBL25555118 | 0.82 | KDM4E (0.63) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| SCHEMBL25555028 | 0.82 | KDM4E (0.63) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| Halostachine SCHEMBL11007060 | 0.82 | KDM4E (0.68) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| Halostachine SCHEMBL932123 | 0.82 | KDM4E (0.68) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| Halostachine SCHEMBL210960 | 0.82 | KDM4E (0.68) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| Halostachine SCHEMBL5076853 | 0.82 | KDM4E (0.68) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| SCHEMBL7532494 | 0.82 | KDM4E (1.00) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 | |
| SCHEMBL4408535 | 0.82 | KDM4E (1.00) | KDM4EL3MBTL1ALDH1A1ADRB2AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | KDM4E 4704/4885L3MBTL1 4370/4885ALDH1A1 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.